Regeneron is in the headlines again: It cut a pricing deal with the Trump administration and won approval for a hearing loss gene therapy. Also, Medicare and the FDA are getting creative with their efforts to speed medical device coverage.
And since it’s totally worth it, sign up for STAT+ between now and Saturday and you’ll get 60% off your first year.
MS drug rejected by FDA gets warmer reception in Europe
From STAT’s Andrew Joseph: A multiple sclerosis drug from Sanofi that was rejected late last year by the FDA found a warmer audience in European regulators, who recommended today that the medicine should be approved.
Continue to STAT+ to read the full story…
<
Leave a Reply